Fri, 30 October 2015
Is the Survival Benefit with Avastin Added to Chemotherapy Enough to Change the Standard of Care in Mesothelioma?
Drs. Ben Solomon, Leora Horn, & Jack West discuss highlights of a French randomized trial that demonstrated a significant survival benefit from addition of Avastin (bevacizumab) to cisplatin/Alimta in patients with malignant pleural mesothelioma.
Direct download: GRACEcast-384_WCLC_2015_Avastin_Chemotherapy_Mesothelioma_Survival_Benefit_Enough.mp4
Category:Lung-Cancer-Video -- posted at: 12:00pm PDT